Radiopharmaceutical Development of Molecular and Targeted Radiotherapy
Radiopharmaceuticals are transforming oncology by delivering radioisotopes directly to tumors with high precision. This enables both diagnostic and therapeutic applications, the foundation of theranostics.
At Oncodesign Services, we support biotechs and biopharma in accelerating the development of innovative radiopharmaceuticals. With deep expertise in oncology and nuclear medicine, we provide an integrated approach that covers every stage of targeted radiotherapy (TRT), from discovery to IND/IMPD-enabling studies.
Radiopharmaceutical development expertise
Radiopharmaceuticals combine the power of radiation with the selectivity of targeted molecules. They enable both diagnostic imaging and therapeutic applications.
Our scientists combine radiochemistry, molecular biology, pharmacology, and imaging to design, test and optimize compounds that improve patient outcomes while reducing risk for biotech programs.
Unlike many CROs focused on single aspects of radioligand therapy, Oncodesign Services facilitates end-to-end support including:
- Bioconjugation
- Radiolabeling
- In vitro assessment
- Affinity
- Internalization
- Toxicity
- In vivo screening
- Biodistribution
- Tolerance
- Efficacy
- Dosimetry
Radionuclide supply chain
In radiopharmaceutical development, securing a radionuclide supply chain is one of the earliest hurdles that must be overcome. Our supply chain provides you with access to over a dozen radionuclides covering alpha and beta therapeutics, PET, and SPECT applications, and includes the recent addition of astatine-211.
Targeted radiotherapy
Our teams specialize in targeted radiotherapy. An approach that uses radiopharmaceuticals to selectively destroy cancer cells while sparing healthy tissue. By leveraging molecular targets, receptor binding, and radioligand design, we ensure precise delivery of therapeutic radioisotopes.
Unlike external beam radiation therapy, where radiation is directed from outside the body, targeted radionuclide therapy involves the internal delivery of radiation. The radiopharmaceutical is usually administered intravenously and circulates through the bloodstream, selectively binding to cancer cells. Once the radiopharmaceutical has bound to the cancer cells, it irradiates the tumor area. These particles have a short range, allowing for localized damage to the targeted cancer cells and not irradiate the surrounding healthy tissues.
The development of radiopharmaceuticals inquires several stages including discovery (to identify and optimize a target that may be treated using radiopharmaceuticals) and preclinical studies (to evaluate the safety, pharmacokinetics and efficacy of the radiopharmaceutical candidate).
This seamless integration ensures faster, de-risked development for biotech innovators.
Oncodesign Services has a unique offer dedicated to preclinical evaluation of radiopharmaceuticals, with a combination of our skills in radiochemistry and in vivo imaging in order to assess systemic radiotherapy efficacy.
With preferred field expert partners, we enable faster and cost-optimized development of your therapeutic, diagnostic or theranostic entity from bioconjugation and radiolabeling up to IND-enabling studies, and even first-in-human.
Why Oncodesign Services?
- End-to-end radiopharmaceutical R&D capabilities
- State-of-the-art radiochemistry and preclinical imaging facilities
- Over 30 years of experience in translational oncology and over a decade in nuclear medicine
- Flexible partnership models to match your program’s needs
Oncodesign Services is your partner of choice for advancing radiopharmaceuticals, from early discovery through clinical development, in molecular and targeted radiotherapy, radioligand therapy, and theranostics.
We partnered with the Oncodesign Services team to support the development of a targetedradiotherapy agent, with the goal of confirming in vivo activity across multiple tumor models anddirectly comparing candidate compounds.
Their radiopharmaceutical expertise was invaluable, particularly in guiding radionuclide comparisonof beta vs alpha emitters and dosing strategies. The project combined “hot” and “cold” studies, a fastcomparative screen with radiolabeling set-up and transfer, biodistribution, PK, anti-tumor efficacyand integrated safety assessments, supporting the nonclinical evaluation of our candidate.
Throughout the project, we appreciated the ODS team’s commitment to timelines and transparentcommunication. Our partnership was well professionally managed through regular open scientificexchanges and a foundation of trust and collaboration.
First-in-Class Radiotherapy Developer (Europe)
